What is the appropriate prescribing information for dasiglucagon (Gvoke) for adults and children with type 1 or type 2 diabetes who are at risk for severe hypoglycemia?

How to Prescribe Gvoke (Dasiglucagon)

Prescribe Gvoke to all patients with diabetes who use insulin or insulin secretagogues (sulfonylureas, meglitinides) at risk for severe hypoglycemia, using weight-based dosing: 0.5 mg for those under 45 kg and 1 mg for those 45 kg or greater. 1, 2

Who Should Receive a Gvoke Prescription

Gvoke should be prescribed for:

• Adults and children aged 2 years and older with type 1 or type 2 diabetes who are treated with insulin 2
• Any patient taking insulin secretagogues (sulfonylureas, meglitinides) 1
• Patients at high risk for severe hypoglycemia, including those with impaired hypoglycemia awareness, history of severe hypoglycemia, or aggressive glycemic targets 1, 3

The 2023 Endocrine Society guideline makes a strong recommendation that glucagon preparations not requiring reconstitution (like Gvoke) should be prescribed over traditional reconstituted glucagon for all at-risk patients 1. This is based on the critical finding that complex reconstitution procedures lead to frequent failure to administer full therapeutic doses, resulting in preventable emergency department visits and hospitalizations.

Dosing Instructions

For Patients Aged 12 Years and Older

• Dose: 1 mg subcutaneously into lower abdomen, outer thigh, or outer upper arm 2
• If no response after 15 minutes, administer an additional 1 mg dose from a new device 2

For Pediatric Patients Aged 2 to Less Than 12 Years

• Weight less than 45 kg: 0.5 mg subcutaneously 2
• Weight 45 kg or greater: 1 mg subcutaneously 2
• If no response after 15 minutes, repeat the appropriate weight-based dose from a new device 2

Critical Administration Points

• Administer as soon as severe hypoglycemia is recognized 2
• Call emergency services immediately after administering the dose 2
• When patient responds, give oral carbohydrates to restore liver glycogen and prevent recurrence 2
• Each device contains a single dose—do not reuse 2

Why Gvoke Over Traditional Glucagon

The evidence strongly favors ready-to-use formulations like Gvoke:

Efficacy: Dasiglucagon achieves plasma glucose recovery in a median of 10 minutes, with 99% of patients recovering within 15 minutes 4, 5. This is comparable to reconstituted glucagon but critically does not include the time needed for reconstitution, which often fails in real-world emergency situations 1.

Ease of Use: The 2023 Endocrine Society guideline panel placed very high value on ease of administration, noting that severe hypoglycemia typically occurs spontaneously (often at night) and is administered by untrained family members in high-stress situations 1. Studies demonstrate caregivers find ready-to-use formulations significantly easier and less intimidating than traditional glucagon requiring reconstitution 1.

Safety Profile: The most common adverse events are nausea (56.5%) and vomiting (24.6%), consistent with all glucagon formulations 5. No serious adverse events, withdrawals, or deaths were reported in placebo-controlled trials 5.

Patient and Caregiver Education

You must educate family members, roommates, school personnel, childcare professionals, coworkers, and anyone in close contact on:

• When to administer Gvoke (signs of severe hypoglycemia: confusion, seizures, loss of consciousness)
• How to use the device (review Instructions for Use at prescription)
• Where the device is stored
• Never administer insulin to someone experiencing hypoglycemia 3

This education is critical because severe hypoglycemia requires help from others to recover 2. The 2023 guideline makes a strong recommendation for structured diabetes education programs for those at high risk 1.

Storage and Replacement

• Store according to product instructions 3
• Replace when reaching expiration date 3
• Keep in original packaging until ready to use 2
• Gvoke's aqueous formulation provides superior stability compared to traditional lyophilized glucagon 6

Age-Specific Considerations

Important caveat: Dasiglucagon (Gvoke) has FDA approval for ages 6 years and older per the guideline discussion 1, though the FDA label states ages 2 years and older 2. For children under 6 years, clinicians must decide whether to use standard glucagon or prescribe Gvoke off-label 1.

Cost-Effectiveness

Modeling studies predict that ready-to-use glucagon formulations like Gvoke are associated with significant annual cost savings due to reduced emergency department visits and hospitalizations from failed administration of traditional glucagon 1.